Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Co-culture model for drug screening in childhood ependymomas

FY 2017-18

Summary
Ependymoma are the third commonest childhood brain tumor. Among their sub­types, posterior fossa (PF) ependymomas, which corresponds to 2/3 of cases with poor prognostic outcome, comprises two distinct molecular profiles: PFA and PFB. PFA ependymomas represent a very high-­risk group with survival rates less than 30%, a worse prognosis than PFB across the entire age spectrum and frequent relapses. It is known that PFA ependymomas are not driven by genetic alterations. However, studies suggest that epigenetic alterations may drive PFA ependymoma. Epigenome analysis revealed that PFA are characterized by DNA hypermethylation in promoter regions, referred to as a CpG island methylator phenotype (CIMP). Altogether, CIMP­-positive PFA ependymomas represent a unique case of a typical epigenetic tumor. Therefore, it is essential to assess the potential of epigenetic drugs on this type of childhood tumors. One limitation of preclinical studies is that 2­-dimension monoculture may not fully recapitulate epigenetic alterations occurring in vivo. This type of experimental approach could also explain the low success rate of newly discovered epigenetic drugs in clinical studies. We hypothesize that developing a co-­culture spheroid model with CIMP-­positive PFA ependymomas and normal glial cells, which are in direct contact with cancer cells in vivo, will allow the development of a better preclinical model. This innovative preclinical approach will allow the discovery of more efficient treatments against those tumors. Using our childhood ependymoma model, we will perform an epigenetic drug screening. Our objective is to discover drug(s) with a potent epigenetic activity against CIMP-­positive PFA ependymoma.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
386494
Name
McInnes Gabrielle
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Co-culture model for drug screening in childhood ependymomas
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr-Cas9 Technology; Drug Discovery; Ependymoma; Epigenetics; In Vitro Model; Pediatric Cancer; Pharmacology; Preclinical Model
Abstract
Ependymoma are the third commonest childhood brain tumor. Among their sub­types, posterior fossa (PF) ependymomas, which corresponds to 2/3 of cases with poor prognostic outcome, comprises two distinct molecular profiles: PFA and PFB. PFA ependymomas represent a very high-­risk group with survival rates less than 30%, a worse prognosis than PFB across the entire age spectrum and frequent relapses. It is known that PFA ependymomas are not driven by genetic alterations. However, studies suggest that epigenetic alterations may drive PFA ependymoma. Epigenome analysis revealed that PFA are characterized by DNA hypermethylation in promoter regions, referred to as a CpG island methylator phenotype (CIMP). Altogether, CIMP­-positive PFA ependymomas represent a unique case of a typical epigenetic tumor. Therefore, it is essential to assess the potential of epigenetic drugs on this type of childhood tumors. One limitation of preclinical studies is that 2­-dimension monoculture may not fully recapitulate epigenetic alterations occurring in vivo. This type of experimental approach could also explain the low success rate of newly discovered epigenetic drugs in clinical studies. We hypothesize that developing a co-­culture spheroid model with CIMP-­positive PFA ependymomas and normal glial cells, which are in direct contact with cancer cells in vivo, will allow the development of a better preclinical model. This innovative preclinical approach will allow the discovery of more efficient treatments against those tumors. Using our childhood ependymoma model, we will perform an epigenetic drug screening. Our objective is to discover drug(s) with a potent epigenetic activity against CIMP-­positive PFA ependymoma.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
McInnes, Gabrielle
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~